The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival using radium-223 (Ra223) in metastatic castrate-resistant prostate cancer (mCRPC) patients with and without DNA damage repair (DDR) defects.
 
Maarten J. van der Doelen
Speakers' Bureau - Astellas Pharma
Research Funding - Bayer Health (Inst); Janssen-Cilag (Inst)
 
Pedro Isaacsson Velho
Honoraria - Bayer
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Pfizer
Research Funding - Bristol-Myers Squibb; Pfizer (Inst)
Expert Testimony - Bayer
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Merck; Merck Serono; Pfizer
 
Peter H.J. Slootbeek
No Relationships to Disclose
 
Samhita Pamidimarri Naga
No Relationships to Disclose
 
Maren Bormann
No Relationships to Disclose
 
Sjoerd van Helvert
No Relationships to Disclose
 
Leonie I. Kroeze
No Relationships to Disclose
 
Inge M. van Oort
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen-Cilag; Sanofi
Research Funding - Astellas Pharma; Bayer; Janssen-Cilag; Sanofi
 
Winald R. Gerritsen
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Sanofi (Inst)
Speakers' Bureau - Bayer; Merck Sharp & Dohme
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen-Cilag (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Niven Mehra
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Genzyme; Janssen-Cilag; MSD Oncology; MSD Oncology (Inst); Roche; Roche
Speakers' Bureau - Roche
Research Funding - Astellas Pharma (Inst); Janssen-Cilag (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; MSD Oncology; Roche